Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas.

The American journal of surgical pathology·2026
Same author

Clinicopathologic and Molecular Features of Poorly Differentiated Thyroid Carcinomas in Adults ≤ 45 Years of Age.

Endocrine pathology·2026
Same author

Treatment of Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples.

PloS one·2025
Same author

Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.

Endocrine pathology·2025
Same author

High-Specificity Detection of UV Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors Using FoundationOne Liquid CDx.

The Journal of molecular diagnostics : JMD·2025

Related Experiment Video

Updated: Apr 16, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.8K

BRAF V600E mutation-specific antibody: A review.

Lauren L Ritterhouse1, Justine A Barletta1

  • 1Department of Pathology, Brigham and Women׳s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115.

Seminars in Diagnostic Pathology
|March 7, 2015
PubMed
Summary

BRAF V600E mutations are key biomarkers in many cancers, driving diagnosis and treatment. Immunohistochemistry offers a practical alternative to molecular testing for BRAF V600E evaluation in tumors.

Keywords:
BRAF V600EColorectal carcinomaImmunohistochemistryMelanomaThyroid carcinoma

More Related Videos

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.8K
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Area of Science:

  • Oncology
  • Molecular Pathology
  • Cancer Biomarkers

Background:

  • BRAF mutations, particularly V600E, are significant in neoplasia, identified in various cancers since 2002.
  • BRAF V600E serves as a critical diagnostic, prognostic, and predictive biomarker, essential for targeted therapies like small-molecule inhibitors in melanoma.
  • Current BRAF mutation testing relies on DNA-based polymerase chain reaction (PCR) assays, which are often time-consuming, costly, and require specialized expertise, limiting accessibility.

Purpose of the Study:

  • To review clinicopathologic features of BRAF-mutant tumors.
  • To discuss the prognostic and predictive implications of BRAF V600E mutations in melanoma, thyroid, and colorectal carcinomas.
  • To evaluate the utility of BRAF V600E immunohistochemistry (IHC) as a diagnostic tool and its correlation with molecular testing.

Main Methods:

  • Review of existing literature on BRAF mutations and their clinical significance.
  • Analysis of clinicopathologic characteristics associated with BRAF-mutant tumors.
  • Discussion of BRAF V600E-specific antibodies (e.g., clone VE1) and their application in immunohistochemistry.

Main Results:

  • BRAF V600E mutations are established biomarkers with significant prognostic and predictive value in several cancer types.
  • Immunohistochemistry using BRAF V600E-specific antibodies provides a viable alternative to molecular testing.
  • Commercial availability of BRAF V600E antibodies facilitates broader clinical application.

Conclusions:

  • BRAF V600E mutation status is crucial for cancer patient management, particularly in melanoma, thyroid, and colorectal cancers.
  • BRAF immunohistochemistry presents a valuable, accessible method for assessing BRAF V600E mutation status in clinical settings.
  • Further research can optimize the integration of BRAF IHC into routine tumor evaluation workflows.